← All trials
NCT07221851
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Mar 31, 2029
- First posted
- Oct 28, 2025
- Last posted
- Nov 10, 2025
- Enrollment
- 186
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascendis Pharma, Inc.Lead sponsor
- Ascendis Pharma, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.